Funding for this research was provided by:
National Institute of Child Health and Human Development (P50HD103526, R01HD074346)
National Center for Advancing Translational Sciences (UL1 TR000002)
Received: 23 November 2020
Accepted: 17 March 2021
First Online: 8 April 2021
: This study was approved by the Institutional Review Board at all participating university sites. Informed written consent was obtained from the parent/legal guardian prior to participation, and assent was obtained from each participant. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and international committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
: Not applicable.
: LA has received funding from F. Hoffmann-La Roche Ltd., Roche TCRC, Inc., Neuren Pharmaceuticals Ltd., Fulcrum Therapeutics, and Lumind to consult on and implement outcome measures in clinical trials for FXS and DS. EBK has received funding from Seaside Therapeutics, Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Neurotrope, Marinus, Zynerba, BioMarin, Lumos, Ovid, AMO, Yamo, Ionis, GeneTx, Acadia, Neurogene, Ultragenyx, and Vtesse/Sucampo/Mallinkcrodt Pharmaceuticals to consult on trial design or development strategies and/or conduct clinical trials in FXS or other genetic neurodevelopmental or neurodegenerative disorders, and from Asuragen Inc. to develop testing standards for <i>FMR1</i> testing. AJT has received funding from Fulcrum Therapeutics to develop outcome measures for FXS. The other authors declare that they have no competing interests.